Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: A population-based study

Carcinogenesis

Volumn 37, Issue 1, 2016, Pages 30-38

  Orlow, Irene ^a   Reiner, Anne S ^a   Thomas, Nancy E ^b   Roy, Pampa ^a   Kanetsky, Peter A ^c   Luo, Li ^d   Paine, Susan ^d   Armstrong, Bruce K ^e   Kricker, Anne ^e   Marrett, Loraine D ^f   Rosso, Stefano ^g   Zanetti, Roberto ^g   Gruber, Stephen B ^h   Anton Culver, Hoda ⁱ   Gallagher, Richard P ^j   Dwyer, Terence ^k   Busam, Klaus ^a   Begg, Colin B ^a   Berwick, Marianne ^d   Parmar, H ^a   Xu, Y ^a   White, K ^l   Cust, A E ^m   Venn, A ⁿ   Tucker, P ⁿ   Kan, D ^j   Theis, E ^f   From, L ^f   Ziogas, A ^o   Johnson, T ^p   Sturgeon, D ^p   Millikan, R C ^q   Ollila, D W ^q   Conway, K ^q   Groben, P A ^q   Edmiston, S N ^q   Hao, H ^q   Parrish, E ^q   Gibbs, D C ^q   Frank, J S ^q   Bramson, J I ^q   Rebbeck, T R ^r   Taylor, J L ^s   Madronich, S ^s   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f CANCER CARE ONTARIO   (Canada)

^g Childhood Cancer Registry of Piedmont   (Italy)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^k UNIVERSITY OF OXFORD   (United Kingdom)

^l UNIVERSITY OF NEW MEXICO   (United States)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ UNIVERSITY OF TASMANIA   (Australia)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p UNIVERSITY OF MICHIGAN   (United States)

^q UNIVERSITY OF NORTH CAROLINA   (United States)

^r UNIVERSITY OF PENNSYLVANIA   (United States)

^s NATIONAL CENTER FOR ATMOSPHERIC RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; VDR PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; GLIOMA; HAPLOTYPE; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; ULCER; AUSTRALIA; CANADA; CLINICAL TRIAL; EPIDEMIOLOGY; GENETICS; ITALY; MELANOMA; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; SKIN TUMOR; UNITED STATES;

AUSTRALIA; CANADA; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; ITALY; MALE; MELANOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CALCITRIOL; SKIN NEOPLASMS; UNITED STATES;

EID: 84954329123     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv157     Document Type: Article

References (86)

1. Howlader, N. et al. SEER Cancer Statistics Review, 1975-2010. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2010/(April 2013 date last accessed).
2. Soong, S.J. et al. (2010) Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann. Surg. Oncol., 17, 2006-2014.
3. de Vries, E. et al. (2008) Superior survival of females among 10, 538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann. Oncol., 19, 583-589.
4. Joosse, A. et al. (2012) Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J. Clin. Oncol., 30, 2240-2247.
5. Lasithiotakis, K. et al. (2008) Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer, 112, 1795-1804.
6. Berwick, M. et al. (2005) Sun exposure and mortality from melanoma. J. Natl Cancer Inst., 97, 195-199.
7. Balch, C.M. et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol., 27, 6199-6206.
8. Davies, J.R. et al. (2014) Inherited variation in the PARP1 gene and survival from melanoma. Int. J. Cancer, 135, 1625-1633.
9. Fang, S. et al. (2015) Association of common genetic polymorphisms with melanoma patient IL-12p40 blood levels, risk, and outcomes. J. Invest. Dermatol., 135, 2266-2272.
10. Li, C. et al. (2013) Polymorphisms of nucleotide excision repair genes predict melanoma survival. J. Invest. Dermatol., 133, 1813-1821.
11. Liu, H. et al. (2012) Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Res., 22, 169-175.
12. Park, J.Y. et al. (2013) Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression. Cancer Epidemiol. Biomarkers Prev., 22, 827-834.
13. Rendleman, J. et al. (2015) Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. J. Med. Genet., 52, 231-239.
14. Yin, J. et al. (2015) Genetic variants in Fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival. J. Invest. Dermatol., 135, 542-550.
15. Afzal, S. et al. (2013) Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. Clin. Chem., 59, 771-780.
16. Bilinski, K. et al. (2013) Association between 25-hydroxyvitamin D concentration and breast cancer risk in an Australian population: an observational case-control study. Breast Cancer Res. Treat., 137, 599-607.
17. Chen, P. et al. (2010) Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res. Treat., 121, 469-477.
18. Engel, P. et al. (2011) Joint effects of dietary vitamin D and sun exposure on breast cancer risk: results from the French E3N cohort. Cancer Epidemiol. Biomarkers Prev., 20, 187-198.
19. Fang, F. et al. (2011) Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One, 6, e18625.
20. Freedman, D.M. et al. (2007) Prospective study of serum vitamin D and cancer mortality in the United States. J. Natl Cancer Inst., 99, 1594-1602.
21. Morton, M.L. et al. (2013) Decreasing 25-hydroxy-vitamin D levels account for portion of the effect of increasing body mass index on breast cancer mortality. Mol. Nutr. Food Res., 57, 260-266.
22. Ng, K. et al. (2008) Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J. Clin. Oncol., 26, 2984-2991.
23. Ordóñez-Mena, J.M. et al. (2013) Serum 25-hydroxyvitamin d and cancer risk in older adults: results from a large German prospective cohort study. Cancer Epidemiol. Biomarkers Prev., 22, 905-916.
24. Pilz, S. et al. (2008) Low serum levels of 25-hydroxyvitamin D predict fatal cancer in patients referred to coronary angiography. Cancer Epidemiol. Biomarkers Prev., 17, 1228-1233.
25. Tretli, S. et al. (2009) Association between serum 25(OH)D and death from prostate cancer. Br. J. Cancer, 100, 450-454.
26. Zgaga, L. et al. (2014) Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J. Clin. Oncol., 32, 2430-2439.
27. Zhou, W. et al. (2007) Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J. Clin. Oncol., 25, 479-485.
28. Zhou, W. et al. (2005) Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol. Biomarkers Prev., 14, 2303-2309.
29. Hansen, C.M. et al. (1998) Down-regulation of laminin-binding integrins by 1 alpha, 25-dihydroxyvitamin D3 in human melanoma cells in vitro. Cell Adhes. Commun., 5, 109-120.
30. Yudoh, K. et al. (1999) 1alpha, 25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J. Lab. Clin. Med., 133, 120-128.
31. Danielsson, C. et al. (1998) Differential apoptotic response of human melanoma cells to 1 alpha, 25-dihydroxyvitamin D3 and its analogues. Cell Death Differ., 5, 946-952.
32. Eisman, J.A. et al. (1987) Suppression of in vivo growth of human cancer solid tumor xenografts by 1, 25-dihydroxyvitamin D3. Cancer Res., 47, 21-25.
33. Evans, S.R. et al. (1996) Vitamin D receptor and growth inhibition by 1, 25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J. Surg. Res., 61, 127-133.
34. Ishibashi, M. et al. (2012) Antiproliferative and apoptosis-inducing effects of lipophilic vitamins on human melanoma A375 cells in vitro. Biol. Pharm. Bull., 35, 10-17.
35. Moan, J. et al. (2008) Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc. Natl Acad. Sci. USA, 105, 668-673.
36. Newton-Bishop, J.A. et al. (2009) Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J. Clin. Oncol., 27, 5439-5444.
37. Rosso, S. et al. (2008) Sun exposure prior to diagnosis is associated with improved survival in melanoma patients: results from a long-term follow-up study of Italian patients. Eur. J. Cancer, 44, 1275-1281.
38. Kim, S.H. et al. (2012) Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer, 77, 265-271.
39. Srinivasan, M. et al. (2011) Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J. Steroid Biochem. Mol. Biol., 123, 30-36.
40. Berger, U. et al. (1991) Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1, 25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res., 51, 239-244.
41. Ditsch, N. et al. (2012) The association between vitamin D receptor expression and prolonged overall survival in breast cancer. J. Histochem. Cytochem., 60, 121-129.
42. Brozyna, A.A. et al. (2011) Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum. Pathol., 42, 618-631.
43. Brozyna, A.A. et al. (2014) Decreased VDR expression in cutaneous melanomas as marker of tumor progression: new data and analyses. Anticancer Res., 34, 2735-2743.
44. Essa, S. et al. (2012) Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines. Anticancer Res., 32, 383-389.
45. Uitterlinden, A.G. et al. (2004) Genetics and biology of vitamin D receptor polymorphisms. Gene, 338, 143-156.
46. Lundin, A.C. et al. (1999) Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group. Cancer Res., 59, 2332-2334.
47. Heist, R.S. et al. (2008) Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J. Clin. Oncol., 26, 5596-5602.
48. Zhou, W. et al. (2006) Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol. Biomarkers Prev., 15, 2239-2245.
49. Obara, W. et al. (2007) Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population. Int. J. Urol., 14, 483-487.
50. Tamez, S. et al. (2009) Vitamin D receptor polymorphisms and prognosis of patients with epithelial ovarian cancer. Br. J. Cancer, 101, 1957-1960.
51. Holt, S.K. et al. (2010) Vitamin D pathway gene variants and prostate cancer prognosis. Prostate, 70, 1448-1460.
52. Shui, I.M. et al. (2012) Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested casecontrol study. J. Natl. Cancer Inst., 104, 690-699.
53. Hama, T. et al. (2011) Prognostic significance of vitamin D receptor polymorphisms in head and neck squamous cell carcinoma. PLoS One, 6, e29634.
54. Zeljic, K. et al. (2012) Vitamin D receptor, CYP27B1 and CYP24A1 genes polymorphisms association with oral cancer risk and survival. J. Oral Pathol. Med., 41, 779-787.
55. Anic, G.M. et al. (2012) An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome. Cancer Causes Control, 23, 1443-1449.
56. Fedirko, V. et al. (2012) Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European populations. Cancer Epidemiol. Biomarkers Prev., 21, 582-593.
57. Goode, E.L. et al. (2002) Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res., 62, 3052-3057.
58. Perna, L. et al. (2013) Vitamin D receptor genotype rs731236 (Taq1) and breast cancer prognosis. Cancer Epidemiol. Biomarkers Prev., 22, 437-442.
59. Orlow, I. et al. (2012) Vitamin D receptor polymorphisms in patients with cutaneous melanoma. Int. J. Cancer, 130, 405-418.
60. Begg, C.B. et al. (2006) A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int. J. Epidemiol., 35, 756-764.
61. Berwick, M. et al. (2006) The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol. Biomarkers Prev., 15, 1520-1525.
62. Fillenbaum, G.G. et al. (2009) Identifying a national death index match. Am. J. Epidemiol., 170, 515-518.
63. Sathiakumar, N. et al. (1998) Using the National Death Index to obtain underlying cause of death codes. J. Occup. Environ. Med., 40, 808-813.
64. Fang, Y. et al. (2005) Promoter and 3'-untranslated-region haplotypes in the vitamin d receptor gene predispose to osteoporotic fracture: the Rotterdam study. Am. J. Hum. Genet., 77, 807-823.
65. Nejentsev, S. et al. (2004) Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum. Mol. Genet., 13, 1633-1639.
66. Boyle, A.P. et al. (2012) Annotation of functional variation in personal genomes using RegulomeDB. Genome Res., 22, 1790-1797.
67. Thomas, N.E. et al. (2013) Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J. Clin. Oncol., 31, 4252-4259.
68. Thomas, N.E. et al. (2014) Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study. JAMA Dermatol., 150, 1306-1314.
69. Fine, J.P. et al. (1999) A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc., 94, 496-509.
70. He, Q. et al. (2013) A general framework for association tests with multivariate traits in large-scale genomics studies. Genet. Epidemiol., 37, 759-767.
71. Lin, D.Y. (2005) An efficient Monte Carlo approach to assessing statistical significance in genomic studies. Bioinformatics, 21, 781-787.
72. Barrett, J.C. et al. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-265.
73. Stephens, M. et al. (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet., 76, 449-462.
74. Stephens, M. et al. (2001) A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet., 68, 978-989.
75. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/(September 2015, date last accessed).
76. Schadt, E.E. et al. (2008) Mapping the genetic architecture of gene expression in human liver. PLoS Biol., 6, e107.
77. Mora, J.R. et al. (2008) Vitamin effects on the immune system: vitamins A and D take centre stage. Nat. Rev. Immunol., 8, 685-698.
78. Trochoutsou, A.I. et al. (2015) Vitamin-D in the immune system: genomic and non-genomic actions. Mini Rev. Med. Chem., 15, 953-963.
79. Halsall, J.A. et al. (2009) The unfavorable effect of the A allele of the vitamin D receptor promoter polymorphism A-1012G has different mechanisms related to susceptibility and outcome of malignant melanoma. Dermatoendocrinology, 1, 54-57.
80. Halsall, J.A. et al. (2004) A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibility and prognosis in malignant melanoma. Br. J. Cancer, 91, 765-770.
81. Hutchinson, P.E. et al. (2000) Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin. Cancer Res., 6, 498-504.
82. Santonocito, C. et al. (2007) Association between cutaneous melanoma, Breslow thickness and vitamin D receptor BsmI polymorphism. Br. J. Dermatol., 156, 277-282.
83. Schäfer, A. et al. (2012) No association of vitamin D metabolism-related polymorphisms and melanoma risk as well as melanoma prognosis: a case-control study. Arch. Dermatol. Res., 304, 353-361.
84. Randerson-Moor, J.A. et al. (2009) Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK casecontrol comparisons and a meta-analysis of published VDR data. Eur. J. Cancer, 45, 3271-3281.
85. Zhao, H. et al. (2014) Whole transcriptome RNA-seq analysis: tumorigenesis and metastasis of melanoma. Gene, 548, 234-243.
86. Fasching, P.A. et al. (2012) The role of genetic breast cancer susceptibility variants as prognostic factors. Hum. Mol. Genet., 21, 3926-3939.